|
US6334997B1
(en)
|
1994-03-25 |
2002-01-01 |
Isotechnika, Inc. |
Method of using deuterated calcium channel blockers
|
|
CN1087725C
(zh)
|
1994-03-25 |
2002-07-17 |
同位素技术有限公司 |
用氘代方法增强药物效果
|
|
TW200418829A
(en)
*
|
2003-02-14 |
2004-10-01 |
Avanir Pharmaceutics |
Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
|
|
EP1613625A1
(en)
|
2003-03-14 |
2006-01-11 |
AstraZeneca AB |
Novel fused triazolones and the uses thereof
|
|
GB0420970D0
(en)
|
2004-09-21 |
2004-10-20 |
Smithkline Beecham Corp |
Novel triazoloquinoline compounds
|
|
AR064416A1
(es)
*
|
2006-12-21 |
2009-04-01 |
Cancer Rec Tech Ltd |
Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
|
|
WO2011075747A1
(en)
|
2009-12-18 |
2011-06-23 |
Glaxosmithkline Llc |
Therapeutic compounds
|
|
WO2017019723A1
(en)
*
|
2015-07-29 |
2017-02-02 |
Merck Sharp & Dohme Corp. |
Aza-cyanoquinolinone pde9 inhibitors
|
|
CN111406050B
(zh)
*
|
2018-01-17 |
2023-02-03 |
厦门宝太生物科技股份有限公司 |
吲哚胺2,3-双加氧酶抑制剂及其用途
|
|
RS64641B1
(sr)
|
2018-06-27 |
2023-10-31 |
Bristol Myers Squibb Co |
Supstituisana jedinjenja naftiridinona korisna kao aktivatori t ćelija
|
|
US11866430B2
(en)
|
2018-06-27 |
2024-01-09 |
Bristol-Myers Squibb Company |
Naphthyridinone compounds useful as T cell activators
|
|
KR20220029719A
(ko)
|
2019-07-04 |
2022-03-08 |
리드 파마 홀딩 비.브이. |
에스트로겐-관련 수용체 알파 조절제
|
|
AR119821A1
(es)
|
2019-08-28 |
2022-01-12 |
Bristol Myers Squibb Co |
Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
|
|
IL291523B2
(en)
|
2019-10-18 |
2023-12-01 |
Lead Pharma Holding Bv |
Estrogen-related receptor alpha (err-alpha) modulators
|
|
US20230062100A1
(en)
|
2019-11-28 |
2023-03-02 |
Bayer Aktiengesellschaft |
Substituted aminoquinolones as dgkalpha inhibitors for immune activation
|
|
US12478621B2
(en)
*
|
2019-11-28 |
2025-11-25 |
Deutsches Krebsforschungszentrum |
Substituted aminoquinolones as dgkalpha inhibitors for immune activation
|
|
WO2021105116A1
(en)
|
2019-11-28 |
2021-06-03 |
Bayer Aktiengesellschaft |
Substituted aminoquinolones as dgkalpha inhibitors for immune activation
|
|
IL294085A
(en)
|
2019-12-19 |
2022-08-01 |
Bristol Myers Squibb Co |
Combinations of dgk inhibitors and checkpoint antagonists
|
|
WO2021133751A1
(en)
|
2019-12-23 |
2021-07-01 |
Bristol-Myers Squibb Company |
Substituted quinazolinyl compounds useful as t cell activators
|
|
MX2022007130A
(es)
|
2019-12-23 |
2022-07-11 |
Bristol Myers Squibb Co |
Derivados de piperazina sustituidos utiles como activadores de celulas t.
|
|
BR112022012220A2
(pt)
|
2019-12-23 |
2022-09-13 |
Bristol Myers Squibb Co |
Compostos de piperazina quinolinonil substituída úteis como ativadores de célula t
|
|
AR120823A1
(es)
|
2019-12-23 |
2022-03-23 |
Bristol Myers Squibb Co |
Compuestos bicíclicos sustituidos útiles como activadores de células t
|
|
ES3013568T3
(en)
*
|
2019-12-23 |
2025-04-14 |
Bristol Myers Squibb Co |
Substituted heteroaryl compounds useful as t cell activators
|
|
EP4445902A3
(en)
|
2019-12-24 |
2024-12-18 |
Carna Biosciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
WO2021258010A1
(en)
|
2020-06-19 |
2021-12-23 |
Gossamer Bio Services, Inc. |
Oxime compounds useful as t cell activators
|
|
CA3202330A1
(en)
|
2020-12-16 |
2022-06-23 |
Anthony Casarez |
Compounds useful as t cell activators
|
|
US11932634B2
(en)
|
2021-06-23 |
2024-03-19 |
Gilead Sciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
EP4359415A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
WO2022271650A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
WO2022271659A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
CN117836296A
(zh)
|
2021-08-03 |
2024-04-05 |
百济神州有限公司 |
吡唑并吡啶酮化合物
|
|
WO2023165525A1
(en)
|
2022-03-01 |
2023-09-07 |
Insilico Medicine Ip Limited |
Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
|
|
WO2023165528A1
(en)
|
2022-03-01 |
2023-09-07 |
Insilico Medicine Ip Limited |
Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
|
|
IL315015A
(en)
|
2022-03-01 |
2024-10-01 |
Insilico Medicine Ip Ltd |
Diacylglycerol kinase (DGK) alpha inhibitors and their uses
|
|
EP4486745A4
(en)
|
2022-03-01 |
2026-03-11 |
Insilico Medicine Ip Ltd |
Diacylglycerol Kinase (DGK) Alpha Inhibitors and Their Uses
|
|
WO2023184327A1
(en)
|
2022-03-31 |
2023-10-05 |
InventisBio Co., Ltd. |
Kinase inhibitors, preparation methods and uses thereof
|
|
JP2025510945A
(ja)
|
2022-03-31 |
2025-04-15 |
インベンティスバイオ カンパニー リミテッド |
キナーゼ阻害剤、その製造方法および用途
|